Studenberg S D, Brouwer K L
Division of Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360.
J Pharmacokinet Biopharm. 1993 Apr;21(2):175-94. doi: 10.1007/BF01059769.
Conventional analysis of initial uptake and egress rates in isolated hepatocytes is limited in the ability to distinguish between rates of metabolite formation and egress, and to separate basolateral and canalicular transport processes. The present study examined the applicability of kinetic modeling in describing acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) formation and egress in hepatocytes after acute exposure to phenobarbital or p-hydroxyphenobarbital glucuronide (p-OHPBG) in vitro, or in vivo phenobarbital pretreatment. A significant pretreatment effect on AG and AS disposition was seen based on initial rates of egress. In vivo phenobarbital pretreatment decreased the initial egress rate of AG compared to vehicle pretreatment, and the initial egress rate of AS compared to all other treatments. A pharmacokinetic model incorporating AG and AS formation in hepatocytes as well as egress processes (including diffusional and active transport components) was fit to the data. Parameter estimates derived from model fits to the data showed the expected increase in acetaminophen glucuronidation and decrease in sulfation after phenobarbital pretreatment; in addition, an increase in the AG diffusional rate constant and a decrease in the AS diffusional rate constant was apparent. The excretion Vmax for AG was decreased statistically after acute phenobarbital exposure in vitro, and in vivo phenobarbital pretreatment, with a concomitant statistical increase in the Km for AG excretion. In vitro acute p-OHPBG exposure also decreased significantly the excretion Vmax for AG. These data are consistent with the hypothesis that phenobarbital-impaired biliary excretion of AG is a function of impaired canalicular transport due to the presence of p-OHPBG. They further suggest that the mechanism may not be simple competitive inhibition. This work demonstrates the utility of a kinetic modeling approach to differentiate metabolic and transport processes when analyzing data from isolated hepatocyte studies. Additional information may be gained that would not be apparent by conventional methods of analysis.
对分离的肝细胞中初始摄取和流出速率的传统分析,在区分代谢物形成速率和流出速率以及分离基底外侧和胆小管转运过程的能力方面存在局限性。本研究考察了动力学建模在描述体外急性暴露于苯巴比妥或对羟基苯巴比妥葡萄糖醛酸苷(p-OHPBG)后,或体内苯巴比妥预处理后,肝细胞中对乙酰氨基酚葡萄糖醛酸苷(AG)和对乙酰氨基酚硫酸酯(AS)的形成及流出情况的适用性。基于初始流出速率,观察到预处理对AG和AS处置有显著影响。与溶剂预处理相比,体内苯巴比妥预处理降低了AG的初始流出速率,与所有其他处理相比,降低了AS的初始流出速率。将一个包含肝细胞中AG和AS形成以及流出过程(包括扩散和主动转运成分)的药代动力学模型与数据进行拟合。从模型拟合数据得到的参数估计显示,苯巴比妥预处理后对乙酰氨基酚葡萄糖醛酸化增加、硫酸化减少,这是预期的结果;此外,AG扩散速率常数增加,AS扩散速率常数降低也很明显。体外急性苯巴比妥暴露后以及体内苯巴比妥预处理后,AG的排泄Vmax在统计学上降低,同时AG排泄的Km在统计学上增加。体外急性p-OHPBG暴露也显著降低了AG的排泄Vmax。这些数据与以下假设一致:苯巴比妥损害AG的胆汁排泄是由于p-OHPBG的存在导致胆小管转运受损。它们进一步表明,其机制可能不是简单的竞争性抑制。这项工作证明了在分析分离肝细胞研究数据时,动力学建模方法在区分代谢和转运过程方面的实用性。可能会获得通过传统分析方法不明显的额外信息。